-
Mashup Score: 0MajesTEC-1: Teclistamab in R/R MM Treatment - 1 year(s) ago
A look at BCMA targeting in relapsed/refractory multiple myeloma treatment and the BCMA-directed bispecific antibody teclistamab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Behind the FDA Approval: Teclistamab for R/R Multiple Myeloma - 1 year(s) ago
In an interview with Targeted Oncology, Alfred L. Garfall, MD, discussed the FDA approval of teclistamab, the MajesTEC-1 trial, and how this information should be used in the future.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Alfred L. Garfall, MD, discussed the #FDA approval of #teclistamab, the MajesTEC-1 trial, and how this information should be used in the future. #mmsm | @PennCancer https://t.co/VzUoRyuhLO
-
-
Mashup Score: 0
Bispecific antibody achieved durable responses in a majority of heavily pretreated patients
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#FDAApproved ✅ Treatment options for relapsed/refractory #multiplemyeloma continue to expand with FDA's #acceleratedapproval of #teclistamab (#Tecvayli). "These are remarkable results," said principal investigator @szusmani of @MSKCancerCenter. https://t.co/Rso0M3wBLA
-
-
Mashup Score: 5Johnson & Johnson's blood cancer therapy gets U.S. FDA approval - 2 year(s) ago
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.
Source: ReutersCategories: Expert Picks, Latest HeadlinesTweet-
J&J's #teclistamab, branded as Tecvayli, has been approved by the FDA for treating adults with multiple #myeloma that is hard to treat or has come back after receiving four or more prior lines of certain classes of therapies. https://t.co/r9Z42n0qhb
-
-
Mashup Score: 1
The first bispecific antibody, teclistamab, receives FDA approval in relapsed/refractory multiple myeloma
Source: www.myelomacrowd.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @MyelomaTeacher: First Bispecific Antibody, #Teclistamab, Now FDA Approved in Multiple Myeloma https://t.co/RA3fOxe9EW @HealthTreeMM #mm…
-
-
Mashup Score: 1
Promising responses including a positive safety profile were seen with teclistamab when used as treatment for patients with relapsed/refractory multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
High rates of deep and durable responses were seen with #teclistamab in patients with triple-class-exposed relapsed/refractory multiple #myeloma, according to updated findings from the phase 1/2 MajesTEC-1 trial. #mmsm https://t.co/j0wdS5bvwq
-
-
Mashup Score: 1Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine — Teclistamab in Relapsed or Refractory Multiple Myeloma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
#Teclistamab in #Relapsed or Refractory #MultipleMyeloma 👇 A nice addition to existing therapies! 👉https://t.co/6OTuSXt4uf @CHUnantes🇫🇷| @Szusmani @DoctorAKrishnan #CD3 https://t.co/iEXvVXQvmf
-
-
Mashup Score: 1Teclistamab in relapsed/refractory multiple myeloma - 3 year(s) ago
Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute and Atrium Health in Charlotte, NC, shares an update on…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase I trial of #Teclistamab, a BCMA and CD3 bispecific antibody, in relapsed/refractory #MultipleMyeloma, w/ @szusmani of @UNC_SOM: https://t.co/8VQD4l4e0e @TheEBMT #EBMT21 #HemOnc #Myeloma #MMSM #CTSM #TrialUpdate #ImmunoOnc
-
-
Mashup Score: 4
1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 2Levine Cancer Institute-Atrium Health, Charlotte, NC, USA; 3Hospital Clinico Universitario de Salamanca, Salamanca, Spain; 4Karolinska University Hospital at Huddinge, Stockholm, Sweden; 5Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, The Netherlands; 6Clínica…
Source: www.oncologysciencehub.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @MAWJNJ: Great presentation by Dr Garfall @AlGarfall at #ASH20 on #teclistamab https://t.co/gAc2mRvZm0 https://t.co/uAssj7hYgL
-
-
Mashup Score: 0Teclistamab for R/R myeloma - 4 year(s) ago
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses a Phase I study of teclistamab, a humanized b-cell maturation…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: #Teclistamab for R/R #Myeloma w/ @mvmateos of @usal: https://t.co/XH5o6weRvQ @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #MMsm #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #ImmunoOnc
-
A look at #BCMA targeting in relapsed/refractory #multiplemyeloma treatment and the BCMA-directed bispecific antibody #teclistamab.@SagarLonialMD @WinshipAtEmory @MDAndersonNews @TulaneMedicine https://t.co/RnkKK5Jsbc